Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan.

ABSTRACT:

Background

The purpose of the study is to evaluate real-world effectiveness and safety of enzalutamide in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) in Japan.

Methods

This was a retrospective evaluation of medical records from men in Japan who started enzalutamide treatment from November 1, 2014, to March 31, 2018, and received androgen deprivation therapy throughout. The primary endpoint was time to prostate-specific antigen (PSA) progression. Secondary endpoints included PSA response rate, time to first use of new antineoplastic therapy, time to first use of cytotoxic chemotherapy, and enzalutamide treatment duration. An exploratory analysis of metastasis-free survival (MFS) was also performed. Adverse events (AEs) were analyzed to assess safety.<

SUBMITTER: Yokomizo A 

PROVIDER: S-EPMC8816761 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature